CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made targeted buys in biotech and cryptocurrency sectors on Tuesday, March 10, capitalizing on recent dips, as shown in ARK’s daily fund disclosures. The funds added a significant stake in CRISPR Therapeutics (CRSP) and 3iQ SOLANA STAKING ETF (SOLQ), alongside a smaller position in GeneDx Holdings (WGS).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
On the sell side, ARK trimmed holdings in gene-sequencing firm 10X Genomics (TXG), offloading 78,412 shares for about $1.60 million. The largest sale was 21,505 shares of automated test equipment maker Teradyne (TER) for $6.47 million. ARK also reduced its position in Brera Holdings (SLMT) by 53,092 shares.
Why ARK Bought CRSP — Is It a Buy?
ARK purchased 280,609 shares of gene-editing firm CRISPR for roughly $14.82 million, snapping up shares after a 10.2% one-day drop. The decline followed CRISPR’s announcement of a $350 million private offering of convertible senior notes due 2031 to qualified investors in a private offering. CRSP will use the net proceeds for general corporate needs, like operations or development. Final terms, including interest rate and conversion prices, will be set at the time of pricing. This news compounded a broader biotech sector pullback.
On TipRanks, CRSP stock has a Moderate Buy consensus rating based on 11 Buys, four Holds, and one Sell rating. The average CRISPR Therapeutics price target of $70.21 implies nearly 33% upside potential from current levels. Over the past year, CRSP shares have surged 24.6%.
ARK’s Bet on Solana Staking — Risks Involved?
ARK also accumulated 25,000 shares in the 3iQ Solana Staking ETF. This provides indirect exposure to Solana (SOL-USD) without directly buying the cryptocurrency. It is designed for investors seeking exposure to blockchain technology through the Solana network. SOLQ is down 5.1% over the past five days.
Unlike Spot ETFs, SOLQ stakes actual Solana tokens, sourced from trusted exchanges and OTC desks, then stores them safely in cold wallets. This cuts risks from middlemen and boosts return potential.
We used TipRanks’ Technical Analysis Tool to assess the outlook for SOLQ ETF. The tool indicates a “Sell” consensus, with three indicators showing Bullish signals, compared to six Neutral and 13 Bearish indicators.
Copyright © 2026, TipRanks. All rights reserved.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US PPI report to test Bitcoin, gold and Nasdaq as December rate hike looms
Nvidia falls to its lowest valuation in 14 years! "Super bull" Tom Lee calls for bottom fishing, retail investors are buying more as it drops, but Wall Street is divided
After the market opened on Thursday, retail investors went against the trend and bought up Nvidia, with net purchases reaching $111 million in just half an hour, setting a record for the same period. Investors such as Tom Lee have publicly supported the company, with institutions optimistic about strong order backlogs extending to 2028, robust revenue growth, and opportunities created by declining valuations. Meanwhile, institutions like Bernstein and Goldman Sachs have become more cautious about Nvidia's outlook, with concerns focusing on management succession and technological leadership following Jensen Huang's departure.
Jane Street boosts Fidelity Bitcoin ETF stake 8x in Q3, trims BlackRock IBIT
From SpaceX to Anthropic, the market has new strategies for dealing with tech giants' IPOs
The market's response strategies to major listings are currently centered around "index inclusion expectations": the new regulations allow mega IPOs to be included in the six major indices within 15 days, triggering concentrated buying by passive funds. Investors are positioning themselves in advance and using options to hedge and amplify buying power. However, Anthropic has a free float of only about 6%; shares available for sale by employees on the first day and privately placed shares with no lock-up period may create supply pressure. On the other hand, index arbitrageurs are facing a rare opportunity.
Crypto prices
More
